Non-gonococcal urethritis (NGU) is an inflammatory condition of the male urethra usually occurring after sexual intercourse. The reported incidence of NGU in England and Wales has doubled since figures were first published a decade ago; in 1960, as estimated from quarterly returns made by V.D. clinics to the Ministry of Health, 21,719 cases were reported.
The aetiology of NGU is unknown. Bacterial activity is generally discounted and the suspected virus or viruses are unidentified. One of the supports of a viral theory has been the prompt response of a high percentage of NGU cases to broad spectrum antibiotics, e.g. the accepted response rate to terramycin is 85 per cent. The broad spectrum antibiotics are not only antibacterial but are antiviral against the larger viruses, and some believe this to be the reason for their success in the treatment of NGU. Any drug therefore with antiviral activity should theoretically be useful in the treatment of NGU. It seemed not unreasonable therefore to treat a series of cases with an antiviral agent having no recognizable antibacterial activity either in vitro or in vivo; such a drug is 17,025.
The antiviral activity of 17,025 has been described by Hurst and Hull (1961) , who showed it to be of very low toxicity in mice, rats, guinea-pigs, and dogs, and to be effective against viruses of the psittacosislymphogranuloma-trachoma group. The compound is non-irritant when administered by the intramuscular route and weight for weight it is rather less than one-tenth as active as chlortetracycline. It was suggested by Hurst and Hull (1961) that its clinical use might perhaps be envisaged when it is desired to 64 control an infection by infrequent parenteral therapy, rather than by prolonged topical application or by frequent oral dosing.
The relationship of the clinical results in mice with the concentration of the drug in the blood, the rate of disappearance from the tissues, and the excretion of unchanged drug in the urine have been examined. These results are presented with a study of the concentration of 17,025 in the blood and urine ofpatients suffering from NGU who were undergoing treatment with the drug. The clinical responses of these patients are discussed.
Clinically 17,025 has been shown to be useful in the treatment of human lymphogranuloma inguinale (Alergant, 1961 17, 025 in the blood and tissues was determined at varying intervals after injection. The drug in the tissues was measured by homogenizing the carcase in water and then estimating the drug using the method described for blood and urine.
Results
After intramuscular injection the rate of disappearance of 17,025 from the tissues of mice appeared to be independent of the dose (Table I) . Over 50 per cent. of the administered dose could not be accounted for in the tissues 24 hours after injection. Although this loss from the tissues was partially accounted for by urinary excretion (Table  II) , the small amounts of 17,025 recovered in the urine (2-6 per cent. of the administered dose) indicated that the drug was being metabolized. The maximum concentrations were not markedly affected by dose, but a straight line relationship was shown to exist between the logarithm of the dose and the area below the "blood level" curve for the 72 hours after injection (Figure) . The concentrations of 17,025 in the blood and urine of patients receiving the drug by one of two dosing schedules were extremely variable (Tables IV and V, opposite), but the results indicated that 17,025 was more persistent in man than it was in mice. Although the urine samples analysed were overnight mid-stream specimens, there was little doubt that as in mice only a small percentage of the administered dose was excreted unchanged.
In four cases Trichomonas vaginalis positive cultures excluded the patients concerned from the trial. Six patients defaulted during or so soon after completion of treatment that no adequate follow-up was possible. These have been excluded from the study.
Of the 23 remaining, fourteen received two injections of 17,025 at a 7-day interval and nine received three injections on days 1, 3, and 7. There was little difference in the response rate of these two groups and therefore all 23 cases are considered together. A total of twelve failed to respond. The remaining eleven were all judged to be "cured" * and were seen at least twice during the first week after completion of treatment. Ten were followed for 2 weeks or more, seven for a month or more, and three for 3 months. Recurrences occurred in two cases; in one 2 weeks and in the other 10 weeks after completion of treatment.
The 33 men originally taking part in this study received a total of 73 injections of 17,025. There was local induration of both buttocks in two patients, and one buttock was affected in three patients. Four others complained of some tenderness at the site of injection. Of the total of nine men complaining, eight also complained of cramps in the thigh and leg muscles.
Discussion
The analytical method which was used will detect 0-5 ,tg. 17,025 per 10 ml. blood or urine. The technique apparently only detected 17,025, as the material extracted from the blood and tissues of injected mice had a similar ultra-violet absorption spectrum and chromatographic mobility to 17,025. In the mouse and in man a high percentage of the administered dose was metabolized, as not more than 10 per cent. could be detected in the urine; faecal excretion was not examined but this appears an unlikely factor.
Variation of the dose administered to mice had little effect on the peak concentration of the drug in the blood, so that the antiviral effect of a particular dose (Table VI, overleaf) in mice would appear to be a function of the persistence of detectable concentrations in the blood. The concentrations of 17,025 found in the blood in man following an initial intramuscular injection of 2 g. were low and variable, although the compound was obviously being absorbed as it was detected in all urine samples examined. Although the drug was still being excreted * "Cured" here means absence of urethral discharge and a clear urine. in the urine 5 to 7 days after this injection, the concentrations of 17,025 in the majority of blood samples taken at this time were below the limit of detection. There appeared to be a better clinical response in the patients in whom 17,025 was more persistent, although the numbers were small. In the second group of patients, therefore, the initial injection was followed after 3 days and then after another 4 days by further injections of 2 g. With this dosage schedule it was hoped that the slightly higher concentrations found in the blood would be sufficient to give a better clinical response. This hope was unfulfilled and there was apparently no relationship between blood concentration or urinary excretion and clinical response.
Summary and Conclusions I.C.I. 17,025, a drug of proven antiviral activity and without detectable antibacterial activity, has been given a clinical trial in NGU, a condition of unproven viral origin. The drug, in the dosages used, proved to be of little value in the treatment of NGU. In mice the concentrations of 17,025 in the blood and the rate of disappearance of the drug from the tissues were correlated with the antiviral activity of the compound.
